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Background: In the general population, reports on suspected ß-lactam hypersensitivity are common. After a drug
allergy work-up at best 20% of the selected patients are positive. However, these considerations have not been
explored in cystic fibrosis patients for whom antibiotics are even more crucial.
Methods: The study, part of the Drug Allergy and Hypersensitivity (DAHD) cohort, was performed in the regional
cystic fibrosis center of Montpellier, France. After identifying patients with a clinical history suggestive of drug
allergy to ß-lactams, a complete drug allergy work-up, was carried out according to the EAACI recommendations.
Results: Among the 171 patients involved, 23 reported clinical manifestations potentially compatible with a drug
allergy to ß-lactams. After performing the complete drug-allergy work-up, 7 were considered as drug hypersensitive
(3 had positive skin tests, 1 a positive provocation test, 3 declined the tests). Excluding the latter 3 patients with
incomplete drug allergy work-up, the rate of proven drug allergy was 2.3%.
Conclusions: Drug allergy to ß-lactams in cystic fibrosis patients is of importance. A full drug allergy work-up is
mandatory in case of suspicion, because ß-lactam responsibility is often ruled out.
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Cystic fibrosis (CF) is a chronic disease for which
chronic therapies are required to slow the progression of
disease [1]. Patients with CF suffer daily symptoms, fre-
quent exacerbations of pulmonary infection, and an early
demise [2]. Chronic airway inflammation and infection
are indeed the greatest causes of mortality and morbidity
in patients with CF, the resulting lung damages being
the main cause of death [1,3,4]. Antibiotics are typically
used for early, intermittent infection, with the goal being
to eradicate the pathogen [2]. Antibacterial therapies are
instituted empirically and are individualized based on
both patient’s factors (severity of exacerbation, frequency* Correspondence: pascal.demoly@inserm.fr
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reproduction in any medium, provided the orof exacerbation, recent courses of anti-infectives) and
pathogen factors (previously isolated pathogens and
in vitro predicted antibiotic susceptibilities) [5].
The French registry on CF reported that, in 2007, more
than 75% of the 4806 patients who underwent a common
cytobacteriologic examination of the sputum (93.5% of
the CF patients treated in France) were infected by a non-
commensal bacteria (mainly Staphylococcus aureus and
Pseudomonas aeruginosa) and, amongst them, 1837
(35.7%) had received at least one course of antibiotics
during the previous year [6].
The frequent use of antibiotics in patients presenting
with CF is often associated to hypersensitivity clinical
manifestations, commonly leading to patients being con-
sidered allergic to one or more antibiotics, and therefore
such drugs being contra-indicate. Thus, the prevalence
of drug allergy is reported to be three times greater (6 to
22%) than the one observed in the general populationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of patients with a suspected
hypersensibility to beta-lactams




Mean age at diagnosis 8.5 (SD 13.3)
Mean age at reaction 21.2 (SD 11.2)
Patients' Genotype (CFTR gene)
F508del/F508del 15 (65.2%)
F508del/R1162 X 1 (4.3%)
F508del/N1303 K 1 (4.3%)
F508del/R553 X 1 (4.3%)
F508del/R1102 X 1 (4.3%)
F508del/3272-2 G> A 1 (4.3%)
Other/other 3 (13.0%)
Bacterium at first reaction
Pseudomonas aer. 11 (47.8%)
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suspected that in many cases the clinical manifestation
was misunderstood, and falsely considered as a drug al-
lergy [10,11].
In the general population, allergy to betalactams (BLs)
is the most frequent cause of drug reaction, mediated by
specific immunological mechanisms [12]. Such reactions
may be induced by all BLs currently available [12]. Such
an assumption has to be true even in patients with CF,
who are much more exposed to these molecules than
the general population. The allergy work-up involves
careful history-taking followed by a drug provocation
test (DPT) when skin tests are negative [12]. If skin tests
and/or DPT are positive, a different BL is often found as
an alternative.
The present study aimed to assess the prevalence of
patients presenting clinical manifestations considered as
a drug allergy to BLs, one of the most commonly used
antibiotics in CF patients. Moreover, the study also
looked for the prevalence of proven drug allergy after a
thorough drug allergy work-up.
Methods
Population
The study was performed over two years (between 2009
and 2011) in the regional CF center of Montpellier, south
of France. This center aimed to manage all patients pre-
senting with a CF in the Languedoc-Roussillon region and
treated according to the international EFS recommenda-
tions. Local ethical committee approved the study design
and protocols. The study was part of the historical-
prospective cohort study Drug Allergy and Hypersensitiv-
ity Database (DAHD). After informing and receiving the
written informed consent from the patients, or from each
parent of minors, the medical referee was asked to iden-
tify and contact those with a clinical history suggestive of
drug allergy to a BL (Table 1).
History
For patient with a suspicion of allergy to BLs, an allergist
trained in drug allergy filled in the standardized ENDA
(European Network for Drug Allergy) questionnaire on
drug allergy [13]. Patients with a suspected hypersensi-
tivity to other classes of antibiotic were not included in
the present study. According to the ENDA protocols for
immediate [14] and non-immediate [15] reactions,
patients with a compatible history of BL allergy under-
went a complete allergy work-up (Table 1).
Skin tests
Skin tests (prick and intradermal) were performed as
previously described [16-18] with the classical benzylpe-
nicillin (penicillin G), semi-synthetic penicillins (amoxi-
cillin and ampicillin) and any other suspected BL. Majorand minor determinants of penicillin G are not commer-
cialized in France. The procedure ended when a positive
skin test was found, according to international guidelines
[14,15]. In patients with an unknown chronology or with
a non-immediate reaction, a late reading of skin tests
was performed [15]. Positive controls for prick tests
were carried out with a histamine solution at 10 mg/ml.
As a negative control for prick and intradermal tests,
normal saline solution was used.
Drug provocation tests (DPT)
In accordance to the ENDA recommendations
[12,14,15], in the case of negative results of skin tests,
provocation tests with the suspected BL were performed
under strict hospital surveillance [10]. Provocation tests
consisted of administering increasing doses of the sus-
pected drug up to the full therapeutic dose or until
symptoms of allergy occurred [10]. Administration was
performed over a one-day hospitalization, by a physician
with full resuscitation back-up. Patients with histories of
anaphylactic reactions had intravenous catheters in place
during the entire test. Patients who had experienced se-
vere reactions, such as toxic epidermal necrolysis,
Stevens-Johnson syndrome, acute generalised exan-
thematous pustolosis, hypersensitivity syndrome or drug
reaction with eosinophilia and systemic symptoms,
blood alterations, nephritis, pneumonitis, hepatitis, and
vasculitis, were not tested since the provocation test is
contra-indicated in such patients [15,19].
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other drugs that could affect skin tests or drug provoca-
tions. Patients on beta-blockers were requested to ask
their cardiologist if they could stop taking the drug for
2 days.
Patient were asked to contact the physician if a reac-
tions occurred in the days following the provocation test
in order to identify delayed reactions.
Statistical analysis
Categorical data were expressed in frequencies and per-
cent, continuous in mean and standard deviation.
Results
Patients and reactions
From 1999 to 2009, the regional referent center on CF
followed 171 patients, 96 (56%) males, with a mean ageFigure 1 Flow chart of the present study and of the results. Legend: BLat diagnosis of 4 years and a mean age at the time when
this study was performed of 18 years. All of them have
been exposed to at least one BL course. Among them
and during this 10-year period, 27 (15.8%) reported a
suspected hypersensitivity reaction to BL antibiotics.
Four (14.8%) out of the 27 patients were excluded since
the clinical presentation of the reaction was considered
as incompatible with a drug allergy by the allergist.
Thus, the proportion of patients with a clinical manifest-
ation potentially compatible with a BL allergy was
restricted to 23 out of 171, 13.5% (Figure 1). One patient
refused to be tested and therefore was excluded from
the present study. Twenty-two patients underwent the
complete drug allergy work-up. Some patients reported
more than one clinical reaction for different ß-lactams,
representing a total of 35 reactions. The most common
drugs involved were ceftazidime (13 – 37.1% of the: Beta-lactam; ST: Skin Tests; DPT: Drug Provocation Test.
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and imipenem (5 – 14.3%). The most severe clinical
reactions presented by the patients were anaphylaxis/
anaphylactic shock (6 – 17.1% of all reactions), followed
by urticaria (7 – 20%), and exanthema (4 – 11.4%).
Twelve patients (54.5%) presented non-immediate reac-
tions, and 10 (45.5%) immediate reactions (i.e. within
the first hour after the last drug intake).
Skin tests and drug provocation tests
All twenty-two patients underwent skin tests and three
were positive, two to one BL only (ticarcillin and pipera-
cillin) and one to two different BLs (ceftazidime and imi-
penem). All skin reactions appeared in the site of the
intradermal test: they occurred at the concentration of
25 mg/ml for piperacillin, ceftazidime and imipenem, and
of 2.5 mg/ml for ticarcillin. Two patients with negative
skin tests refused the DPT. For twenty patients, at least
one DPT was then performed, either with the culprit drug
(the 17 remaining negative skin tests patients) or with an
alternative when the culprit one was skin test positive.
Two patients had a positive DPT, both of them for cefta-
zidime, one with previous negative skin tests and one with
a positive skin test to ticarcillin. The first patient showed
a generalized urticaria, 20 minutes after the end of the
test (total amount of administered drug: 2,816 grams),
while the second one presented a periorbital angioedema,
associated with cough right after the administration of a
dose of 10 mg of ceftazidime (total amount of adminis-
tered drug: 16 mg). Three patients presenting multiple
histories of suspected drug hypersensitivity to BLs, under-
went 2 different DPTs, both of which resulted negative.
Therefore, assuming that patients who did not undergo
the full drug allergy work-up were sensitized (without any
proof other than the clinical presentation and the refusal
of the test), 7 patients should be considered as sensitized
(4 by drug allergy work-up, 2 who declined the provoca-
tion test and 1 who did not undergo the drug allergy
work-up). This represented a rate of 4.1% of the total CF
cohort or around one third (30.4%) of the patients report-
ing a clinical history of BL allergy (Figure 1). Excluding
the three patients with incomplete drug allergy work-up,
the rate of proven drug allergy was 2.3%.
Follow-up
A 12-months follow-up of the twenty patients was also
conducted. One year after the DPT, all patients had at
least one new BL antibiotic course. Sixteen patients were
re-administered, at least once, the same drug negatively
tested. Only one of them re-resented some clinical mani-
festation after the drug intake, consisting in generalized
pruritus and treated by an H1-antihistamine drug, but
without stopping the antibiotic course. As for the two
patients who resulted to be positive to the DPT, one, foran unknown reason, had a new course of ceftazidime (the
drug resulted positive during the DPT) and reacted dur-
ing the course. Nevertheless, both of them, received, dur-
ing the 12-months follow-up a BL course with a safe
alternative.
Discussion
The mechanism of acquisition and maintenance of bac-
terial infection in the airways of patients with CF is un-
clear [1]. Bacterial growth in biofilms in the CF airway is
associated with decreased susceptibility to antibiotics,
even when given in combination [1]. The large amount of
prescribed antibiotics is correlated with a major risk of
developing hypersensitivity reactions. Such a consider-
ation is even more important knowing that the major in-
crease in life expectancy of CF patients is due to a better
management of infections [7], and to the wide use of anti-
biotics [3,4].
This observational historico-prospective study reported
27 (15.8%) suspicions of drug allergy to BLs in 171 CF
patients. After performing a full drug-allergy work-up in
patients with a suspicion, 4.1% of the patients (30.4% of
the patients with a suspicion) were considered as allergic
to BL and in 2.3% the allergy was proved by our work-up.
These finding suggested that BL drug allergy is not un-
common in CF. However, the rate of sensitized patients
could even be overestimated since we considered patients
without full drug-allergy work-up as sensitized. The CF
specialist in charge of the patient selected all patients who
reported for the last 10 years a clinical reaction consid-
ered as a BL drug allergy. It is very unlikely that the refer-
ring doctor, not specialized in drug allergy, could have
missed some patients' reactions, because all adverse
events are systematically asked for and listed in the pa-
tient files by the CF medical team. Therefore, the initial
rate of 15.8% (27 out of 171) patients with a clinical pres-
entation considered as an allergic reaction to BL is a real-
ity. The relatively low rate of “true” sensitized patients,
and the good negative predictive value of the BL work-up
[20] should encouraged the referring doctor to report the
suspicions to a drug allergy specialist.
Some could argue that the present study has a selection
bias since it is an observational study focused on a single
clinical centre. However, since 2002 the French "Centres
de Ressources et de Compétences de la Mucoviscidose"
have been created in order to coordinate CF health care,
including treatment. These centers cover the whole popu-
lation, based on the patients’ location. Therefore, such
bias should be limited and similar results should be
observed for the whole national CF population.
Conclusions
Drug allergy to BLs in CF patients is of importance since
many patients report clinical presentations suggestive of
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not a true drug allergy and a full drug allergy work-up is
recommended. Otherwise there will be a loss of chance
for these patients who often require BLs, and for whom
the control of the infection is a major factor of their life
expectancy.
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